14-day Double Therapy Versus Bismuth Quadruple Therapy in First-line Treatment of Helicobacter Pylori Infection

• Status: Not yet recruiting
• Trial end date: 2023-06-20
• Target enrollment: 0
• Participant gender: All

Summary

The researchers collected untreated H. pylori positive patients from outpatient clinics. Subjects were randomized to 14 days of dual therapy with Tegoprazan or 14 days of quadruple therapy with bismuth for eradication. At 6 weeks after treatment, subjects underwent another 13C-urea breath test. The eradication rate, adverse reaction rate and patient compliance were calculated.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shandong University
• Treatments: Amoxicillin

Criteria

Inclusion Criteria:

• Helicobacter pylori infection (either positive for Helicobacter pylori culture, histopathological test, rapid urease test, C13/C14 urea breath test, or helicobacter pylori antigen test in feces).

• Patients who have not previously received helicobacter pylori eradication therapy.

Exclusion Criteria:

• Serious underlying diseases, such as liver insufficiency, renal insufficiency, immunosuppression, malignant tumor, coronary heart disease (angina pectoris or coronary artery stenosis ≥ 75%).

• Those who are not willing to take contraceptive measures during pregnancy, lactation or the trial.

• Active gastrointestinal bleeding.

• History of drug allergy.

• Medication history of bismuth, antibiotics and PPI within 4 weeks.

• Other behaviors that may increase the risk, such as alcohol and drug abuse.

• Unable or unwilling to provide informed consent.